B-cell maturation antigen (BCMA) is a transmembrane protein member of the tumor necrosis factor (TNF) receptor superfamily, predominantly expressed on plasma cells, including malignant myeloma cells.1-3 Preclinical studies have shown that BCMA is essential for the survival of these cell types.1,3 Therefore, BCMA is a promising target protein in multiple myeloma through investigational therapies such as chimeric antigen receptor (CAR) T cell therapy, bispecific T-cell engagers, and antibody drug conjugates, among others.1,2

BCMA molecular pathway research

View areas of research related to BCMA (CAR T, TCE, ADC)


  1. Seckinger A, et al. Cancer Cell. 2017;31:396-410. PMID: 28262554
  2. Tai Y, Anderson K. Immunotherapy. 2015;7:1187-1199. PMID: 26370838
  3. O'Connor BP, et al. J Exp Med. 2004;199:91-98. PMID: 14707116